Dr. Furberg is a molecular epidemiologist conducting research to identify factors associated with genitourinary cancer etiology and prognosis. She is Co-PI of the MSK Urothelial Cancer Registry, an institutional resource to identify genetic and non-genetic factors associated with bladder cancer risk and outcomes. She is PI of an American Cancer Society-funded grant to conduct a prospective study to determine the impact of post-diagnosis smoking on bladder cancer recurrence risk and BCG treatment. She is also funded to identify germline genetic variants that are associated with response to platinum-based chemotherapy in bladder cancer patients. Together with clinical colleagues at MSK and at Weill Cornell, she is investigating the prognostic relevance of body size in urologic malignancies with an emphasis on the obesity paradox in kidney cancer.